News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,209 Results
Type
Article (43686)
Company Profile (473)
Press Release (694038)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209329)
Career Advice (2039)
Deals (36153)
Drug Delivery (119)
Drug Development (83971)
Employer Resources (174)
FDA (16689)
Job Trends (15188)
News (354169)
Policy (33279)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2656)
Accelerated approval (34)
Adcomms (28)
Allergies (145)
Alliances (51119)
ALS (178)
Alzheimer's disease (1726)
Antibody-drug conjugate (ADC) (328)
Approvals (16926)
Artificial intelligence (543)
Autoimmune disease (157)
Automation (38)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (192)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (60)
Breast cancer (649)
Cancer (4926)
Cardiovascular disease (418)
Career advice (1724)
Career pathing (38)
CAR-T (292)
CDC (46)
Celiac Disease (2)
Cell therapy (780)
Cervical cancer (36)
Clinical research (71435)
Collaboration (1797)
Company closure (4)
Compensation (1177)
Complete response letters (64)
COVID-19 (2771)
CRISPR (96)
C-suite (878)
Cystic fibrosis (152)
Data (6306)
Decentralized trials (2)
Denatured (39)
Depression (142)
Diabetes (504)
Diagnostics (6748)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (267)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (244)
Earnings (91399)
Editorial (60)
Employer branding (21)
Employer resources (153)
Events (120994)
Executive appointments (1006)
FDA (19838)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1533)
Gene editing (212)
Generative AI (45)
Gene therapy (646)
GLP-1 (1010)
Government (4757)
Grass and pollen (6)
Guidances (384)
Healthcare (19204)
HIV (60)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (274)
Immuno-oncology (61)
Indications (110)
Infectious disease (3041)
Inflammatory bowel disease (197)
Inflation Reduction Act (17)
Influenza (118)
Intellectual property (251)
Interviews (315)
IPO (16932)
IRA (52)
Job creations (3713)
Job search strategy (1440)
JPM (66)
Kidney cancer (15)
Labor market (85)
Layoffs (581)
Leadership (33)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (665)
Lymphoma (380)
Machine learning (43)
Management (59)
Manufacturing (811)
MASH (170)
Medical device (13921)
Medtech (13974)
Mergers & acquisitions (20300)
Metabolic disorders (1318)
Multiple sclerosis (165)
NASH (19)
Neurodegenerative disease (339)
Neuropsychiatric disorders (97)
Neuroscience (3015)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4583)
Now hiring (67)
Obesity (631)
Opinion (281)
Ovarian cancer (168)
Pain (204)
Pancreatic cancer (232)
Parkinson's disease (294)
Partnered (34)
Patents (496)
Patient recruitment (498)
Peanut (57)
People (60313)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22470)
Phase 2 (31500)
Phase 3 (23279)
Pipeline (5303)
Policy (295)
Postmarket research (2602)
Preclinical (9607)
Press Release (67)
Prostate cancer (245)
Psychedelics (56)
Radiopharmaceuticals (298)
Rare diseases (891)
Real estate (6064)
Recruiting (71)
Regulatory (24995)
Reports (52)
Research institute (2485)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3805)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (82)
Vaccines (1027)
Venture capital (95)
Weight loss (409)
Women's health (91)
Worklife (19)
Date
Today (128)
Last 7 days (605)
Last 30 days (2137)
Last 365 days (30781)
2026 (3353)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47417)
2018 (35697)
2017 (33032)
2016 (32350)
2015 (38406)
2014 (32189)
2013 (27124)
2012 (29226)
2011 (29868)
2010 (27999)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (317)
Arkansas (14)
Asia (40702)
Australia (6762)
California (11470)
Canada (3296)
China (1139)
Colorado (486)
Connecticut (492)
Delaware (338)
Europe (89213)
Florida (1687)
Georgia (358)
Hawaii (3)
Idaho (61)
Illinois (880)
India (66)
Indiana (524)
Iowa (24)
Japan (436)
Kansas (130)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1401)
Massachusetts (8344)
Michigan (326)
Minnesota (637)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3054)
New Mexico (31)
New York (3004)
North Carolina (1532)
North Dakota (9)
Northern California (5576)
Ohio (336)
Oklahoma (21)
Oregon (45)
Pennsylvania (2298)
Puerto Rico (24)
Rhode Island (48)
South America (1122)
South Carolina (65)
South Dakota (1)
Southern California (4448)
Tennessee (175)
Texas (1765)
United States (40796)
Utah (340)
Vermont (1)
Virginia (267)
Washington D.C. (82)
Washington State (955)
West Virginia (4)
Wisconsin (113)
Wyoming (2)
738,209 Results for "allay therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Allay Therapeutics Announces Development and Commercialization Agreement with Maruishi Pharmaceutical for Ultra-Sustained Pain Therapeutics in Japan
Allay Therapeutics, Inc. (Allay) today announced that they have entered into a license agreement with Maruishi Pharmaceutical Co., Ltd. (Maruishi), providing Maruishi with exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
December 18, 2023
·
4 min read
Press Releases
Allay Therapeutics Announces $57.5M Series D Financing and Venture Debt Line to Advance ATX101 and its Ultra-Sustained Pain Platform for Post-Surgical Pain Management
June 5, 2025
·
7 min read
Business
Allay Therapeutics Appoints Nicole Vitullo to Board of Directors
Allay Therapeutics announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.
September 6, 2023
·
2 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Press Releases
Oncotelic Therapeutics, Inc. Showcases Multi-Year Execution and Validation, Enters 2026 with Late-Stage Momentum Across Diversified Pipeline
February 10, 2026
·
7 min read
Press Releases
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million
January 16, 2026
·
8 min read
Press Releases
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 2, 2026
February 3, 2026
·
2 min read
Drug Development
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced the results from a Phase 2B clinical study of its lead investigational product ATX101.
April 11, 2024
·
7 min read
Drug Development
Allay Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application to Initiate Pivotal Phase 2B Trial of ATX101 for the Treatment of Post-Surgical Pain Following Total Knee Replacement Surgery
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, announced plans to proceed to a Phase 2b registration trial of its lead investigational product ATX101.
June 12, 2024
·
4 min read
1 of 73,821
Next
